γ-谷氨酰转肽酶与胆碱酯酶及血小板比值预测慢性乙型肝炎显著肝纤维化及肝硬化
该研究纳入2343例慢性乙型肝炎患者,按肝活检时间分为早期和晚期队列,以Scheuer标准定义显著纤维化(≥S2)和肝硬化(≥S4),比较GCPR与GPR预测效能。结果显示GCPR在预测显著纤维化和肝硬化方面的AUROC均显著高于GPR,GCPR>0.080单cutoff下特异度和敏感度在不同HBeAg状态和队列中均有报告。
要点
- GCPR预测显著纤维化和肝硬化的AUROC均显著高于GPR。
- GCPR>0.080时,HBeAg阳性患者预测显著纤维化特异度早期83.3%、晚期88.2%、完整85.0%。
- GCPR>0.080时,HBeAg阴性患者预测肝硬化敏感度早期83.1%、晚期82.1%、完整82.7%。
核心结论
- GCPR在预测慢性乙型肝炎显著肝纤维化和肝硬化方面性能高于GPR。
研究设计与样本
- 完整队列2343例慢性乙型肝炎患者,按肝活检时间分为早期和晚期队列。
- 以Scheuer标准定义肝病理分期≥2期为显著纤维化,≥4期为肝硬化。
- 采用受试者工作特征曲线评估模型性能。
主要发现
- 早期队列中,GCPR预测HBeAg阳性患者显著纤维化的AUROC为0.782,高于GPR的0.748(Z=8.198,p<0.0001)。
- 早期队列中,GCPR预测HBeAg阴性患者显著纤维化的AUROC为0.775,高于GPR的0.747(Z=6.023,p<0.0001)。
- 早期队列中,GCPR预测HBeAg阳性患者肝硬化的AUROC为0.842,高于GPR的0.802(Z=6.686,p<0.0001)。
- 早期队列中,GCPR预测HBeAg阴性患者肝硬化的AUROC为0.861,高于GPR的0.823(Z=6.116,p<0.0001)。
- GCPR>0.080时,早期、晚期和完整队列中预测HBeAg阳性患者显著纤维化的特异度分别为83.3%、88.2%和85.0%,HBeAg阴性患者分别为87.6%、87.4%和87.6%;预测HBeAg阳性患者肝硬化的敏感度分别为81.9%、88.7%和84.2%,HBeAg阴性患者分别为83.1%、82.1%和82.7%。
关键数值与推荐
- GCPR预测显著纤维化:HBeAg阳性早期队列AUROC 0.782,HBeAg阴性早期队列AUROC 0.775。
- GCPR预测肝硬化:HBeAg阳性早期队列AUROC 0.842,HBeAg阴性早期队列AUROC 0.861。
- GCPR>0.080单cutoff下,HBeAg阳性患者预测显著纤维化特异度早期83.3%、晚期88.2%、完整85.0%。
- GCPR>0.080单cutoff下,HBeAg阴性患者预测显著纤维化特异度早期87.6%、晚期87.4%、完整87.6%。
- GCPR>0.080单cutoff下,HBeAg阳性患者预测肝硬化敏感度早期81.9%、晚期88.7%、完整84.2%,HBeAg阴性患者早期83.1%、晚期82.1%、完整82.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the performance of a new mathematical model γ-glutamyl transpeptidase to cholinesterase and platelet ratio (GCPR) versus γ-glutamyl transpeptidase to platelet ratio (GPR) in predicting significant fibrosis and cirrhosis of chronic hepatitis B. METHODS: A complete cohort of 2343 patients was divided into early and late cohort depending on the time of liver biopsy. With reference to the Scheuer standard, liver pathologic stage 2 or higher and stage 4 or higher were defined as significant fibrosis and cirrhosis, respectively. Receiver operating characteristic (ROC) curve was used to evaluate the performance of investigated models. RESULTS: In the early cohort, the areas under ROC curves (AUROCs) of GCPR in predicting significant fibrosis of hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients (0.782 and 0.775) were both significantly greater than those of GPR (0.748 and 0.747) (Z = 8.198 and Z = 6.023, both p <0.0001); the AUROCs of GCPR in predicting cirrhosis of HBeAg-positive and HBeAg-negative patients (0.842 and 0.861) were both significantly greater than those of GPR (0.802 and 0.823) (Z = 6.686 and Z = 6.116, both p <0.0001). In early, late and complete cohorts, using a single cutoff of GCPR > 0.080, the specificities of GCPR in predicting significant fibrosis of HBeAg-positive patients were 83.3%, 88.2% and 85.0% and of HBeAg-negative patients were 87.6%, 87.4% and 87.6%, respectively; and the sensitivities of GCPR in predicting cirrhosis of HBeAg-positive patients were 81.9%, 88.7% and 84.2% and of HBeAg-negative patients were 83.1%, 82.1% and 82.7%, respectively. CONCLUSIONS: GCPR has higher performance than GPR in predicting significant fibrosis and cirrhosis of chronic hepatitis B.
引用
- Liu D, Li J, Lu W, et al. Gamma-glutamyl transpeptidase to cholinesterase and platelet ratio in predicting significant liver fibrosis and cirrhosis of chronic hepatitis B. Clin Microbiol Infect. 2018. PMID: 29906588. doi:10.1016/j.cmi.2018.06.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。